Resumen de las cotizaciones máximas, mínimas y variaciones del Invivyd
Precios históricos de las acciones
Precio actual de la acción	US$0.80
Máximo en las últimas 52 semanas	US$3.07
Mínimo de 52 semanas	US$0.48
Beta	0.67
Cambio en 1 mes	-18.82%
Variación en 3 meses	-54.34%
Cambio de 1 año	7.82%
Variación en 3 años	-41.76%
Variación en 5 años	n/a
Variación desde la OPV	-96.15%

Noticias y actualizaciones recientes

Actualización de narrativa • Jun 23

IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside

Analysts have kept their $10.00 price target on Invivyd steady, citing the recent post earnings selloff as overdone, given that the Q1 revenue shortfall and higher $30.7 million research and development spend are viewed as timing related and tied to pivotal investments ahead of the key VYD2311 data readout and potential biologics license application. What’s in the News for Invivyd Invivyd completed enrollment in the Phase 3 DECLARATION trial of VYD2311, assessing a single intramuscular dose and monthly dosing versus placebo for prevention of symptomatic COVID-19 over 90 days, with approximately 2,400 participants enrolled.

Actualización de narrativa • Jun 05

IVVD: Phase 3 Prophylaxis Progress And BLA Pathway Will Drive Upside

Narrative Update on Invivyd Analysts have reaffirmed a $10 price target for Invivyd, citing the view that the recent post earnings selloff tied to a Q1 revenue miss and higher research and development spend was overdone. Upcoming VYD2311 data and a potential biologics license application are seen as the main drivers for maintaining this valuation level.

Recent updates

Actualización de narrativa • Jun 23

IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside

Actualización de narrativa • Jun 05

IVVD: Phase 3 Prophylaxis Progress And BLA Pathway Will Drive Upside

Actualización de narrativa • Apr 26

IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside

Analysts have adjusted their price target on Invivyd to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. They are keeping fair value around $10.00 per share while fine tuning the risk and profitability profile that underpins the estimate.

Actualización de narrativa • Apr 11

IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside

Analysts have adjusted their price target on Invivyd to $10.00 from $10.00, reflecting updated views on discount rate, revenue growth expectations, profit margin and future P/E assumptions. What's in the News Invivyd reported progress in the REVOLUTION clinical program for VYD2311, including the pivotal DECLARATION Phase 3 study assessing VYD2311 for pre-exposure COVID-19 prophylaxis versus placebo over 90 days, with a blinded sample size re-estimation that triggered an upsizing of approximately 500 subjects to support statistical power.

Actualización de narrativa • Mar 26

IVVD: Phase 3 COVID Prevention And Long COVID Trial Will Drive Upside

Narrative Update on Invivyd Analysts have modestly adjusted their price view on Invivyd, with the updated fair value holding at $10.00. Small tweaks to discount rate, revenue growth, profit margin assumptions, and a higher future P/E estimate of about 282x refine the underlying model rather than signal a major shift in conviction.

Seeking Alpha • Mar 20

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

Summary Invivyd, Inc. is advancing VYD2311, a next-gen monoclonal antibody for COVID-19 prevention, with pivotal Phase 3 DECLARATION data expected mid-2026. IVVD's Pemgarda generated $53.4M in 2025 revenue, but fell short of management expectations; net loss narrowed to $(52.5M) from $(170M) prior year. IVVD secured FDA Fast Track for VYD2311 and raised ~$200M in 2H 2025, providing at least two years of funding at current burn rates. I view IVVD stock as a high-risk, high-reward opportunity; DECLARATION study success could drive shares up 75%, but failure could see stock revisit sub-$0.5 levels. Read the full article on Seeking Alpha

Actualización de narrativa • Mar 10

IVVD: Fast Track Phase 3 COVID Prevention Program Will Drive Future Upside

Analysts have adjusted their price target on Invivyd to reflect updated assumptions around revenue growth of 71.06%, a profit margin of 5.97% and a future P/E of 266.11x. These assumptions result in a revised fair value estimate of $10.00 per share.

Actualización de narrativa • Feb 23

IVVD: Phase 3 Fast Track COVID Prevention Trials Will Support Future Upside

Analysts have kept their fair value estimate for Invivyd steady at $10.00. A slightly lower discount rate and modestly softer profit margin outlook, paired with a marginally higher future P/E assumption, reflect a more finely balanced view of the company’s risk and earnings potential.

Actualización de narrativa • Feb 09

IVVD: Phase 3 Fast Track COVID Prevention Program Will Drive Future Upside

Analysts have trimmed their price target on Invivyd to US$10, citing updated assumptions that include a slightly higher discount rate, modestly reduced profit margin expectations, and a higher future P/E multiple. What's in the News FDA granted Fast Track designation for VYD2311, Invivyd's vaccine alternative monoclonal antibody candidate for prevention of COVID in individuals with underlying risk factors for severe disease, aligning the program with an expedited U.S. regulatory process (Key Developments).

Artículo de análisis • Jan 29

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

The Invivyd, Inc. ( NASDAQ:IVVD ) share price has softened a substantial 26% over the previous 30 days, handing back...

Actualización de narrativa • Jan 24

IVVD: REVOLUTION Program Will Define Future Upside As COVID Prevention Alternative

Analysts have lifted their price target on Invivyd to US$10 from US$5, citing the launch of the REVOLUTION clinical program for VYD2311 as a key driver behind their updated view. Analyst Commentary Analysts are reacting to the REVOLUTION program for VYD2311 as a key event for Invivyd, and the updated US$10 price target reflects how they are recalibrating risk and potential upside around this new clinical path.

Actualización de narrativa • Jan 08

IVVD: REVOLUTION Program And Fast Track Status Will Support Future Upside Potential

Narrative Update on Invivyd Analysts have lifted their price target on Invivyd to US$10 from US$5, pointing to the launch of the REVOLUTION clinical program for VYD2311 as a key factor that they believe strengthens the company’s regulatory and commercial position. Analyst Commentary Recent Street research around Invivyd has focused squarely on the launch of the REVOLUTION clinical program for VYD2311, with bullish analysts recalibrating their expectations for the company’s potential market position and execution risk.

Actualización de narrativa • Dec 18

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION clinical program for VYD2311 as a meaningful inflection point that enhances the company’s regulatory and commercial outlook. Analyst Commentary Following the launch of the REVOLUTION clinical program for VYD2311, equity research has focused on how the new data and development path could reshape Invivyd's long term growth and valuation profile.

Actualización de narrativa • Dec 04

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION program for VYD2311 as a key inflection point that improves the company's regulatory and commercial outlook. Analyst Commentary Analysts interpreting the updated price target see the REVOLUTION program as a pivotal moment for Invivyd, shifting expectations for both execution and long term growth potential.

Artículo de análisis • Nov 29

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Despite an already strong run, Invivyd, Inc. ( NASDAQ:IVVD ) shares have been powering on, with a gain of 27% in the...

Actualización de narrativa • Nov 20

IVVD: REVOLUTION Program Initiation Will Drive Regulatory Momentum and Commercial Outlook

Analysts have raised their price target for Invivyd from $5 to $10, citing the launch of the REVOLUTION clinical program as a pivotal development. This new program is expected to enhance the company's regulatory and commercial outlook.

Actualización de narrativa • Nov 05

IVVD: FDA Clearance and REVOLUTION Program Launch Signal Strong Upside Ahead

Narrative Update: Invivyd Analyst Price Target Increased Invivyd's analyst price target has been raised from $5.67 to $7.33 per share. Analysts cite strengthened commercial and regulatory prospects following the launch of the REVOLUTION clinical program.

Actualización de narrativa • Oct 22

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Narrative Update on Invivyd: Analyst Price Target Revision Analysts have maintained Invivyd's price target at $5.67, citing consistent profit margin expectations along with only minor adjustments to the discount rate and future earnings estimates. What's in the News The FDA has cleared Invivyd's Investigational New Drug application, advancing the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Product-Related Announcements).

Artículo de análisis • Oct 14

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Invivyd, Inc. ( NASDAQ:IVVD ) shares have continued their recent momentum with a 31% gain in the last month alone. The...

Actualización de narrativa • Oct 08

Internal Sales And Antibody Pipeline Will Broaden Patient Reach

Narrative Update on Invivyd Price Target Analysts have raised Invivyd’s price target from $3.00 to $5.67, citing updated forecasts and changes in market expectations. What's in the News The U.S. FDA cleared Invivyd’s Investigational New Drug application, enabling advancement of the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Key Developments).

Artículo de análisis • Aug 22

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Invivyd, Inc. ( NASDAQ:IVVD ) shareholders that were waiting for something to happen have been dealt a blow with a 31...

Actualización de narrativa • Aug 16

Internal Sales And Antibody Pipeline Will Broaden Patient Reach

Invivyd’s fair value estimate has been sharply reduced, driven by lowered revenue growth projections and a decline in expected net profit margins, resulting in a consensus analyst price target drop from $4.93 to $2.93. What's in the News Invivyd’s monoclonal antibody pemivibart (PEMGARDA) has shown strong protection (84% relative risk reduction) against symptomatic COVID-19 in immunocompromised and at-risk populations in the placebo-controlled CANOPY Phase 3 trial, supporting its Emergency Use Authorization (EUA) for pre-exposure prophylaxis.

Nueva narrativa • Apr 23

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025

The development of next-generation antibodies could expand market reach and improve margins by lowering production and administration costs.

Seeking Alpha • Feb 04

I See The Bull Case For Invivyd, But I'm Not Married To It

Summary Invivyd, Inc. focuses on developing antibody-based treatments for infectious diseases, primarily COVID-19, with promising projects like PEMGARDA and VYD2311. Strong Q4 performance with a 48% revenue increase for PEMGARDA and a 55% drop in operating expenses highlights Invivyd's potential for profitability. VYD2311 shows significant promise with high neutralization potency and durability, but faces regulatory and competitive challenges before market approval. Invivyd is a speculative bet with potential for high rewards; suitable for risk-tolerant investors, but stability seekers should avoid. Read the full article on Seeking Alpha

Artículo de análisis • Feb 01

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Artículo de análisis • Jul 16

Here's Why We're Watching Invivyd's (NASDAQ:IVVD) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Artículo de análisis • Mar 29

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, Invivyd ( NASDAQ:IVVD...

Artículo de análisis • Oct 24

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Rentabilidad de los accionistas

	IVVD	US Biotechs	Mercado US
7D	-10.1%	3.4%	-0.4%
1Y	7.8%	37.9%	18.4%

Rentabilidad vs. Industria: Los resultados de IVVD fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 37.9% el año pasado.

Rentabilidad vs. Mercado: IVVD obtuvo unos resultados inferiores a los del mercado US, que fueron del 18.4% el año pasado.

Volatilidad de los precios

Is IVVD's price volatile compared to industry and market?
IVVD volatility
IVVD Average Weekly Movement	13.0%
Biotechs Industry Average Movement	10.5%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Precio estable de las acciones: El precio de las acciones de IVVD ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IVVD ha disminuido de 20% a 13% en el último año, pero sigue siendo superior al 75% de los valores de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2020	122	Bill Duke	www.invivyd.com

Invivyd, Inc. junto con sus filiales, se dedica a la investigación, desarrollo, comercialización y venta de terapias con anticuerpos para la prevención y el tratamiento de enfermedades infecciosas víricas en Estados Unidos. La empresa ofrece Pemivibart, un anticuerpo monoclonal en investigación de semivida prolongada para la prevención profiláctica previa a la exposición al COVID-19 en adultos y adolescentes mediante inyección con la marca PEMGARDA. También desarrolla VYD2311, un anticuerpo monoclonal, que está en fase III de ensayo clínico para la prevención y el tratamiento del virus SARS-CoV-2; y VBY329, un anticuerpo monoclonal, que está en fase de ensayo preclínico para la prevención y el tratamiento del virus respiratorio sincitial y el sarampión en neonatos, lactantes y niños.

Resumen de fundamentos de Invivyd, Inc.

¿Cómo se comparan los beneficios e ingresos de Invivyd con su capitalización de mercado?
Estadísticas fundamentales de IVVD
Capitalización bursátil	US$244.52m
Beneficios(TTM)	-US$77.60m
Ingresos (TTM)	US$55.87m

4.2x

Ratio precio-ventas (PS)

-3.1x

Ratio precio-beneficio (PE)

¿Está IVVD sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IVVD
Ingresos	US$55.87m
Coste de los ingresos	US$3.95m
Beneficio bruto	US$51.92m
Otros gastos	US$129.52m
Beneficios	-US$77.60m

Últimos beneficios comunicados

Mar 31, 2026

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.26
Margen bruto	92.94%
Margen de beneficio neto	-138.90%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado IVVD a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/07/09 00:31
Precio de las acciones al final del día	2026/07/09 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Invivyd, Inc. está cubierta por 5 analistas. 3 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Thomas Shrader	BTIG
Joshua Schimmer	Cantor Fitzgerald & Co.
Patrick Trucchio	H.C. Wainwright & Co.

Invivyd (IVVD) Resumen de Acciones

Recompensas

Análisis de riesgos

Analyst Price Targets

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Regulatory Risks And Competition Will Impede Gains But Yield Promise

Rapid Antibody Advances Will Leverage Secular Pandemic Trends

Top Analyst Narratives

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Regulatory Risks And Competition Will Impede Gains But Yield Promise

Rapid Antibody Advances Will Leverage Secular Pandemic Trends

Competidores de Invivyd, Inc.

Keros Therapeutics

Korro Bio

X4 Pharmaceuticals

CapForce

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Invivyd, Inc. Receives Notice of Termination for Pemgarda Emergency Use Authorization and Provides Update on Next Steps with Fda

FDA Sets June 2027 End Date for Emergency Use of Invivyd’s PEMGARDA

IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside

Invivyd, Inc. Completes Enrollment In Phase 3 Liberty Clinical Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd, Inc. Doses First Participants In Liberty Phase 3 Clinical Trial To Evaluate VYD2311 Antibody Versus Mrna Covid Vaccine and to Characterize Safety And Immunology Of Antibody and mRNA Vaccine Co-Administration

IVVD: Phase 3 Prophylaxis Progress And BLA Pathway Will Drive Upside

Recent updates

Invivyd, Inc. Receives Notice of Termination for Pemgarda Emergency Use Authorization and Provides Update on Next Steps with Fda

FDA Sets June 2027 End Date for Emergency Use of Invivyd’s PEMGARDA

IVVD: Phase 3 Prophylaxis Readouts And BLA Prospect Will Drive Upside

Invivyd, Inc. Completes Enrollment In Phase 3 Liberty Clinical Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

Invivyd, Inc. Doses First Participants In Liberty Phase 3 Clinical Trial To Evaluate VYD2311 Antibody Versus Mrna Covid Vaccine and to Characterize Safety And Immunology Of Antibody and mRNA Vaccine Co-Administration

IVVD: Phase 3 Prophylaxis Progress And BLA Pathway Will Drive Upside

Consensus revenue estimates fall by 25%

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Price target increased by 76% to US$10.00

Invivyd Sees Wider Loss and Share Decline as Pipeline Spending Rises and Revenue Misses Estimates

Invivyd Authors New Manuscript Evaluating Early Tolerability Of COVID Monoclonal Antibody And Comparing Results To COVID Vaccination

IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside

IVVD: Phase 3 COVID Prophylaxis Progress Will Drive Future Upside

Invivyd, Inc Announces Progress in Revolution Program and Advancement of Novel Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd, Inc., Annual General Meeting, May 19, 2026

IVVD: Phase 3 COVID Prevention And Long COVID Trial Will Drive Upside

Invivyd: A Logical Bull Thesis With A Major Catalyst Approaching

IVVD: Fast Track Phase 3 COVID Prevention Program Will Drive Future Upside

Invivyd, Inc. Appoints Michael Mina, M.D., Ph.D. As Chief Medical Officer

IVVD: Phase 3 Fast Track COVID Prevention Trials Will Support Future Upside

IVVD: Phase 3 Fast Track COVID Prevention Program Will Drive Future Upside

Invivyd Aligns with the U.S. Fda on Liberty, A Phase 3 Trial to Evaluate the Safety of Vyd2311 Antibody Versus Mrna Covid Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine

Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk

IVVD: REVOLUTION Program Will Define Future Upside As COVID Prevention Alternative

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

IVVD: REVOLUTION Program And Fast Track Status Will Support Future Upside Potential

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

Optimistic Investors Push Invivyd, Inc. (NASDAQ:IVVD) Shares Up 27% But Growth Is Lacking

Invivyd, Inc. Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329

IVVD: REVOLUTION Program Initiation Will Drive Regulatory Momentum and Commercial Outlook

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $124.9994 million.

IVVD: FDA Clearance and REVOLUTION Program Launch Signal Strong Upside Ahead

Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Internal Sales And Antibody Pipeline Will Broaden Patient Reach

Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd, Inc. Appoints Kristie Kuhl as Chief Communications Officer

SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd's VYD2311 At Recover-TLC Workshop

Invivyd, Inc. has completed a Follow-on Equity Offering in the amount of $49.997866 million.

Why Investors Shouldn't Be Surprised By Invivyd, Inc.'s (NASDAQ:IVVD) 31% Share Price Plunge

Invivyd, Inc. has filed a Follow-on Equity Offering.

Invivyd, Inc. Announces Continued Neutralizing Activity of PEMGARDA®? (Pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG

Invivyd, Inc. Aligns with U.S. FDA on Rapid Pathway to Full Approval of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Internal Sales And Antibody Pipeline Will Broaden Patient Reach

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long Covid and Covid-19 Post-Vaccination Syndrome

Invivyd, Inc. Announces Positive Full Phase 1/2 Clinical Data for VYD2311, A Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Publication of Landmark CANOPY Phase 3 Pemivibart Clinical Trial

Invivyd, Inc. Announces Inclusion of PEMGARDA (Pemivibart) in National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd, Inc. Commends FDA Focus on Contemporary Evidence in Evaluating Medical Interventions to Prevent Covid-19

Invivyd, Inc. Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies for Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Pemivibart And Next-Generation VYD2311 Will Empower Market Expansion By 2025